Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Phase 2 Completed
73 enrolled 12 charts
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
Phase 1/2 Completed
60 enrolled 11 charts
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Phase 1/2 Completed
9 enrolled 8 charts
Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Phase 2 Completed
31 enrolled 5 charts
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
Phase 2 Completed
90 enrolled 10 charts
Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2 Completed
60 enrolled 13 charts
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
Phase 2 Completed
53 enrolled 15 charts
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
Phase 2 Completed
73 enrolled 13 charts
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Phase 2 Completed
252 enrolled 20 charts
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Phase 2 Completed
46 enrolled 13 charts
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
Phase 2 Completed
361 enrolled 12 charts
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase 1/2 Completed
92 enrolled 24 charts
Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Phase 1/2 Completed
48 enrolled 14 charts
Mel47
Phase 2 Completed
17 enrolled 12 charts
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
Phase 2 Completed
87 enrolled 11 charts
MAESTRO HN
Phase 2 Completed
86 enrolled 11 charts
Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
Phase 2 Completed
36 enrolled 12 charts
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
Phase 1 Completed
15 enrolled
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase 1 Completed
3 enrolled
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Phase 1 Completed
72 enrolled
Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
Phase 1 Completed
11 enrolled
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Completed
21 enrolled
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery
Phase 2 Completed
70 enrolled 8 charts
Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery
Phase 2 Completed
38 enrolled 5 charts
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
Phase 2 Completed
178 enrolled 6 charts
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Phase 1 Completed
13 enrolled
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
Phase 1/2 Completed
69 enrolled 12 charts
Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1 Completed
40 enrolled
Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
Phase 2 Completed
62 enrolled 7 charts
Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
38 enrolled
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
18 enrolled
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase 2 Completed
89 enrolled 9 charts
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
Phase 2 Completed
109 enrolled 8 charts
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
Phase 1 Completed
39 enrolled
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
71 enrolled 10 charts
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
Phase 1 Completed
69 enrolled
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Phase 1 Completed
72 enrolled
CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma
Phase 2 Completed
27 enrolled
Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 Completed
25 enrolled
Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma
Phase 1 Completed
25 enrolled
CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 2 Completed
33 enrolled
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
Phase 2 Completed
50 enrolled
CCI-779 in Treating Patients With Prostate Cancer
Phase 2 Completed
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
Phase 2 Completed
55 enrolled
CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
42 enrolled
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
Phase 1 Completed
28 enrolled
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1 Completed
24 enrolled
CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Phase 2 Completed
80 enrolled
Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function
Phase 1 Completed
130 enrolled
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
Phase 2 Completed
74 enrolled